bpc-157 unapproved new drug fda BPC 157 Banned: Key Facts on the Latest Decision FDA moves BPC-157 to Category

10 The prohibition applies to BPC-157 rather than only to one particular salt description

2026 Milestone The human trial the field has been waiting for February 2026 First Properly Designed Randomised Controlled Trial Now Recruiting Hudson Biotech began recruiting for the first randomised, placebo-controlled, blinded trial of BPC-157 in humans in February 2026 a Phase 2 study that represents the pivotal transition from preclinical to clinical evidence

Step 3: Rebuild the barrier

You can find additional information about the risks of FDA-approved medications that contain semaglutide here

Thymosin-1 (T1

The immediate release version suits those focused purely on gut healing where local effects matter most